The University of Pittsburgh Virology Specialty Laboratory will test various samples provided (nasopharyngeal swabs, throat swabs, and saliva) using EUA approved testing platforms from ThermoFisher and Hologic for patients testing for SARS-CoV-2 to increase the United States testing capacity. Testing volume will depend on sample delivery and test kit availability. Capacity will initially approximate 25-50 samples today, ramping up to 100-200 per day with a sufficient supply chain for reagents. The Ohio State University Medical Center’s Clinical Laboratories are significantly increasing their testing capacity using multiple platforms for PCR and serologic testing (e.g. CDC, DiaSorin, Abbott to name a few). Using the Medical Center’s CLIA-certified testing venues, we propose to develop a protocol to identify, test and obtain clinical history from defined populations who are not in the top tier for priority testing.